Erratum: Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of ApoE-deficient mice (Arteriosclerosis, Thrombosis, and Vascular Biology (2009) 29 (1478-1480) DOI: 10.1161/ATVBAHA.109.190264);Expression of human ApoAII in transgenic rabbits leads to dyslipidemia: A new model for combined hyperlipidemia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 12, 2009, Pages 2047-2053

  Koike, Tomonari ^a   Kitajima, Shuji ^b   Yu, Ying ^a   Li, Ying ^a   Nishijima, Kazutoshi ^b   Liu, Enqi ^c   Sun, Huijun ^d   Waqar, Ahmed Bilal ^a   Shibata, Nobumitsu ^a   Inoue, Tomoriho ^a   Wang, Yao ^a   Zhang, Bo ^e   Kobayashi, Junji ^f   Morimoto, Masatoshi ^g   Saku, Keijiro ^e   Watanabe, Teruo ^h   Fan, Jianglin ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b SAGA UNIVERSITY   (Japan)

^c MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^d DALIAN MEDICAL UNIVERSITY   (China)

^e FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^g KUMAMOTO HEALTH SCIENCE UNIVERSITY   (Japan)

^h FUKUOKA WAJIRO HOSPITAL   (Japan)

Author keywords

Apolipoprotein; HDL; Hyperlipidemia; Lipase; Transgenic rabbits

Indexed keywords

APOLIPOPROTEIN A2; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LIPOPROTEIN LIPASE; PHOSPHOLIPID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; ENZYME ACTIVITY; HUMAN; HYPERLIPIDEMIA; LIPID ANALYSIS; LIPOPROTEIN METABOLISM; NONHUMAN; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; TRANSGENIC ANIMAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 73849142402     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATV.0b013e3181de4b0b     Document Type: Erratum

References (35)

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707-714.
2. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov. 2005;4:193-205.
3. Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med. 2008;263:256-273.
4. Blanco-Vaca F, Escola-Gil JC, Martin-Campos JM, Julve J. Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J Lipid Res. 2001;42:1727-1739.
5. Martin-Campos JM, Escola-Gil JC, Ribas V, Blanco-Vaca F. Apoli-poprotein A-II, genetic variation on chromosome 1q21-q24, and disease susceptibility. Curr Opin Lipidol. 2004;15:247-253.
6. Kalopissis AD, Pastier D, Chambaz J. Apolipoprotein A-II: beyond genetic associations with lipid disorders and insulin resistance. Curr Opin Lipidol. 2003;14:165-172.
7. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of tri-glyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol. 1997;17:715-722.
8. Birjmohun RS, Dallinga-Thie GM, Kuivenhoven JA, Stroes ES, Otvos JD, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM. Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. Circulation. 2007;116:2029-2035
9. van't Hooft FM, Ruotolo G, Boquist S, de Faire U, Eggertsen G, Hamsten A. Human evidence that the apolipoprotein a-II gene is implicated in visceral fat accumulation and metabolism of triglycer-ide-rich lipoproteins. Circulation. 2001;104:1223-1228.
10. Deeb SS, Takata K, Peng RL, Kajiyama G, Albers JJ. A splice-junction mutation responsible for familial apolipoprotein A-II deficiency. Am J Hum Genet. 1990;46:822-827.
11. Escola-Gil JC, Blanco-Vaca F, Julve J. Overexpression of human apoli-poprotein A-II in transgenic mice does not increase their susceptibility to insulin resistance and obesity. Diabetologia. 2002;45:600-601.
12. Castellani LW, Goto AM, Lusis AJ. Studies with apolipoprotein A-II transgenic mice indicate a role for HDLs in adiposity and insulin resistance. Diabetes. 2001;50:643-651.
13. Castellani LW, Nguyen CN, Charugundla S, Weinstein MM, Doan CX, Blaner WS, Wongsiriroj N, Lusis AJ. Apolipoprotein AII is a regulator of very low density lipoprotein metabolism and insulin resistance. J Biol Chem. 2008;283:11633-11644.
14. Schultz JR, Verstuyft JG, Gong EL, Nichols AV, Rubin EM. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature. 1993;365:762-764.
15. Warden CH, Hedrick CC, Qiao JH, Castellani LW, Lusis AJ. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science. 1993;261:469-472.
16. Escola-Gil JC, Marzal-Casacuberta A, Julve-Gil J, Ishida BY, Ordonez-Llanos J, Chan L, Gonzalez-Sastre F, Blanco-Vaca F. Human apoli-poprotein A-II is a pro-atherogenic molecule when it is expressed in transgenic mice at a level similar to that in humans: evidence of a potentially relevant species-specific interaction with diet. J Lipid Res. 1998;39:457-462.
17. Tailleux A, Bouly M, Luc G, Castro G, Caillaud JM, Hennuyer N, Poulain P, Fruchart JC, Duverger N, Fievet C. Decreased susceptibility to diet-induced atherosclerosis in human apolipoprotein A-II transgenic mice. Arterioscler Thromb Vasc Biol. 2000;20:2453-2458.
18. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23: 160-167.
19. Fan J, Watanabe T. Transgenic rabbits as therapeutic protein bioreactors and human disease models. Pharmacol Ther. 2003;99:261-282.
20. Chapman MJ. Animal lipoproteins: Chemistry, structure, and comparative aspects. J Lipid Res. 1980;21:789-853.
21. Marzal-Casacuberta A, Blanco-Vaca F, Ishida BY, Julve-Gil J, Shen J, Calvet-Marquez S, Gonzalez-Sastre F, Chan L. Functional lecithin:cho-lesterol acyltransferase deficiency and high density lipoprotein deficiency in transgenic mice overexpressing human apolipoprotein A-II. J Biol Chem. 1996;271:6720-6728.
22. Recillas-Targa F, Pikaart MJ, Burgess-Beusse B, Bell AC, Litt MD, West AG, Gaszner M, Felsenfeld G. Position-effect protection and enhancer blocking by the chicken beta-globin insulator are separable activities. Proc Natl Acad Sci U S A. 2002;99:6883-6888.
23. Fan J, Unoki H, Kojima N, Sun H, Shimoyamada H, Deng H, Okazaki M, Shikama H, Yamada N, Watanabe T. Overexpression of lipoprotein lipase in transgenic rabbits inhibits diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem. 2001;276:40071-40079.
24. Bu X, Warden CH, Xia YR, De Meester C, Puppione DL, Teruya S, Lokensgard B, Daneshmand S, Brown J, Gray RJ, Rotter JI, Lusis AJ. Linkage analysis of the genetic determinants of high density lipoprotein concentrations and composition: evidence for involvement of the apoli-poprotein A-II and cholesteryl ester transfer protein loci. Hum Genet. 1994;93:639-648.
25. Alaupovic P, Knight-Gibson C, Wang CS, Downs D, Koren E, Brewer HB Jr, Gregg RE. Isolation and characterization of an apoA-II-containing lipoprotein (LP-A-II:B complex) from plasma very low density lipoproteins of patients with Tangier disease and type V hyperlipopro-teinemia. J Lipid Res. 1991;32:9-19.
26. Boisfer E, Lambert G, Atger V, Tran NQ, Pastier D, Benetollo C, Trottier JF, Beaucamps I, Antonucci M, Laplaud M, Griglio S, Chambaz J, Kalopissis AD. Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis. J Biol Chem. 1999;274:11564-11572.
27. Tailleux A, Duriez P, Fruchart JC, Clavey V. Apolipoprotein A-II, HDL metabolism and atherosclerosis. Atherosclerosis. 2002;164:1-13.
28. Tall AR, Small DM. Plasma high-density lipoproteins. N Engl J Med. 1978;299:1232-1236.
29. Mowri HO, Patsch JR, Gotto AM Jr, Patsch W. Apolipoprotein A-II influences the substrate properties of human HDL2 and HDL3 for hepatic lipase. Arterioscler Thromb Vasc Biol. 1996;16:755-762.
30. Thuren T, Wilcox RW, Sisson P, Waite M. Hepatic lipase hydrolysis of lipid monolayers. Regulation by apolipoproteins. J Biol Chem. 1991;266: 4853-4861.
31. Zhong S, Goldberg IJ, Bruce C, Rubin E, Breslow JL, Tall A. Human ApoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice. J Clin Invest. 1994;94:2457-2467.
32. Weng W, Brandenburg NA, Zhong S, Halkias J, Wu L, Jiang XC, Tall A, Breslow JL. ApoA-II maintains HDL levels in part by inhibition of hepatic lipase. Studies In apoA-II and hepatic lipase double knockout mice. J Lipid Res. 1999;40:1064-1070.
33. Warren RJ, Ebert DL, Mitchell A, Barter PJ. Rabbit hepatic lipase cDNA sequence: low activity is associated with low messenger RNA levels. J Lipid Res. 1991;32:1333-1339.
34. Allayee H, Castellani LW, Cantor RM, de Bruin TW, Lusis AJ. Biochemical and genetic association of plasma apolipoprotein A-II levels with familial combined hyperlipidemia. Circ Res. 2003;92:1262-1267.
35. Aouizerat BE, Kane JP. Apolipoprotein A-II: active or passive role in familial combined hyperlipidemia. Circ Res. 2003;92:1179-1181.